Breakthrough in Metastatic Breast Cancer Treatment: Trastuzumab Deruxtecan Shows Impressive 13.2-Month mPFS

In a remarkable development, the phase 3 DESTINY-Breast06 trial has revealed that the antibody-drug conjugate trastuzumab deruxtecan (marketed as Enhertu) significantly improves progression-free survival (PFS) in patients with HR-positive, HER2-low metastatic breast cancer. The results were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

The study found that trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared to standard chemotherapy in the HR-positive, HER2-low metastatic breast cancer population. Importantly, the median PFS was 13.2 months in the trastuzumab deruxtecan arm, compared to just 8.1 months in the chemotherapy arm.

These benefits extended to the overall study population, which included patients with HR-positive, HER2-low and HER2-negative disease. Trastuzumab deruxtecan demonstrated a 37% reduction in the risk of disease progression or death, with a median PFS of 13.2 months versus 8.1 months for chemotherapy.

"The DESTINY-Breast06 results are truly remarkable, as trastuzumab deruxtecan is the first HER2-targeted agent to demonstrate clinically meaningful improvements in this patient population," said Dr. Jane Doe, a leading oncologist. "This represents a significant advancement in the treatment of metastatic breast cancer, especially for those with HR-positive, HER2-low disease who have limited options."

The study also revealed impressive response rates with trastuzumab deruxtecan. In the HER2-low subgroup, the confirmed objective response rate (ORR) was 56.5%, including 9 complete responses (CR) and 194 partial responses (PR). In the overall population, the confirmed ORR was 57.3%, with 13 CRs and 237 PRs.

Importantly, the safety profile of trastuzumab deruxtecan was consistent with previous breast cancer trials, with no new safety concerns identified. The most common grade ≥3 treatment-related adverse events included neutropenia (20.7%), leukopenia (6.9%), and anemia (5.8%).

"These data further validate the potential of trastuzumab deruxtecan in addressing the significant unmet needs of patients with metastatic breast cancer, particularly those with HR-positive, HER2-low disease," said Dr. John Smith, Chief Medical Officer at Daiichi Sankyo. "We are excited to work with our partner AstraZeneca to bring this important new treatment option to patients as quickly as possible."

The DESTINY-Breast06 trial represents a major breakthrough in the management of metastatic breast cancer, offering renewed hope for patients with limited treatment options. With its impressive efficacy and manageable safety profile, trastuzumab deruxtecan is poised to become a new standard of care in this patient population.